Loading...
NASDAQ: BIIB
Biogen Inc.
Healthcare · Drug Manufacturers - General
●S&P 500 since 2003
Market Cap
$27.02B
52w High
$202.41
52w Low
$110.04
P/E
20.89
Volume
95.02K
Outstanding Shares
146.76M
Company profile
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases.
CEOChristopher A. Viehbacher
SectorHealthcare
IndustryDrug Manufacturers - General
Employees7,605
IPO dateSep 17, 1991
Valuation
Forward P/E—
EV/EBITDA9.60
Enterprise value$29.76B
Stock splits
Jan 18, 20013:1
Dec 21, 19992:1
Profitability & growth
Revenue growth-7.15%
Gross margin70.47%▼7.42%vs FY2024
Operating margin19.14%▼25.64%vs FY2024
ROE7.08%▼27.45%vs FY2024
Analyst consensus
RatingBuy
Target price$206.76▲12.28%
25
Buy
21
Hold
1
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
View
EPS
Actual vs estimate by quarter
Q2FY25
ActualEst.
$5.47
$3.90
Q3FY25
ActualEst.
$4.81
$3.88
Q4FY25
ActualEst.
$1.99
$1.63
Q1FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2FY25
ActualEst.
$2.65B
$2.33B
Q3FY25
ActualEst.
$2.45B
$2.34B
Q4FY25
ActualEst.
$2.28B
$2.2B
Q1FY26
Next Est.
—